Researchers from Kanaph Therapeutics Inc. have reported the discovery and preclinical evaluation of a small-molecule EGFR inhibitor, KNP-501, being developed as an anticancer agent.
Cell cycle dysregulation in cancer cells represents a clinical option for treating cancer, by using cyclin-dependent kinase 4/6 (CDK4/6) inhibitory agents. Further evaluation on this approach was presented by TYK Medicines Inc., where they focused on the pharmacological action of a CDK7 inhibitor TY-2699a for the potential treatment of cancer.
Halia Therapeutics Inc. has reported the development of tyrosine-protein kinase receptor TYRO3 inhibitors potentially useful for the treatment of glioma.
Cullgen (Shanghai) Inc. has patented proteolysis targeting chimera (PROTAC) compounds comprising a DDB1 binding moiety covalently bonded to a target protein binding moiety through a linker. They are reported to be useful for the treatment of cancer.
Researchers from TYK Medicines Inc. have reported the discovery and preclinical evaluation of TY-1091, a second-generation RET inhibitor being developed for the treatment of RET-mutant cancers.
Data on the poly(ADP-ribose) glycohydrolase (PARG) inhibitor SYX-3759, being investigated for the treatment of homologous recombination deficient (HRD) malignancies, were recently discussed by researchers from Hangzhou Synrx Therapeutics Technology Co. Ltd.
IL-18 is a pro-inflammatory cytokine that triggers IFN-γ production and increases T- and NK-cell activity. IL-18’s effects are blocked by IL-18 binding protein (IL-18BP), an endogenous protein that binds to IL-18 with high affinity and that is highly present in the tumor microenvironment (TME).
RSS
